Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorTanta University
About this trial
This study aims to investigate the possible safety and efficacy of Zinc sulphate as antifibrotic agent in chronic HBV patient receiving antiviral therapy.
Eligibility criteria
Qualifiers
Patients with fibrosis stage (F2&F3) post chronic HBV infection receiving standard antiviral therapy.
Age > 18 and < 65 years.
Disqualifiers
Patients with prior history of liver transplantation.
Patients with prior history of hepatocellular carcinoma.
Patients coinfected with HIV or HCV.
Patients with any malignancies.
Trial design
Treatments tested in this trial
- Entecavir (ETV)
- Zinc (zinc sulphate)
Treatment groups
44 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov